European Generics Applications Fall, As EMA’s Interim Report Hopes To Herald Funding Renewal
This article was originally published in The Pink Sheet Daily
Executive Summary
European Commission intervention has stopped duplicate generic applications. EMA hopes to end its budget row with the EU Parliament by focusing on transparency and conflict of interest disclosures.
You may also be interested in...
EU SCOPE Project Will Harmonize Pharmacovigilance, Benefit Industry
The EU SCOPE pharmacovigilance project will harmonize practices across the 28 member states, thereby cutting the administrative and cost burden for pharmaceutical manufacturers.
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA’s plans for access to clinical trials data not set to be ready until well into 2014.
EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation
Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.